Premarket Decliner
LYRA Lyra Therapeutics13.38+1.08+8.8%
Premarket:10.02-3.36 (-25.1%)
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Globe NewswireFri, 27-Jun 8:00 AM
LYRA Lyra Therapeutics4.74+0.02 (+0.4%)
Premarket Gainer
LYRA Lyra Therapeutics4.32+0.20+4.9%
Premarket:5.32+1.00 (+23.2%)
Lyra Therapeutics Announces $100.5 Million Private Placement
PRNewswireFri, 8-Apr 7:34 AM
After Hours Gainer
LYRA Lyra Therapeutics7.87-0.38-4.6%
After Hours:9.58+1.71 (+21.7%)
Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis
Business WireTue, 8-Jun 4:30 PM
After Hours:9.30+1.43 (+18.2%)
LYRA Lyra Therapeutics7.63+0.45+6.3%
Premarket:9.00+1.37 (+18.0%)
Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets
Business WireWed, 2-Jun 7:00 AM
